A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
-
BUSINESS COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
-
REGULATORY Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
-
REGULATORY 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
-
BUSINESS Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
March 30, 2022
-
REGULATORY Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
-
REGULATORY Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
-
ORGANIZATION FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
-
REGULATORY Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
-
REGULATORY Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
-
REGULATORY Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
-
REGULATORY Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
-
REGULATORY Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
-
REGULATORY AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
-
ORGANIZATION Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
-
BUSINESS Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
March 22, 2022
-
BUSINESS Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years
March 18, 2022
-
REGULATORY MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
-
BUSINESS Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
-
COMMENTARY Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
March 16, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…